Follow-up for low blood counts without MDS
Part of Blood & lymphatic clinical trials.
This study follows people with ongoing low blood counts (red cells, white cells, and/or platelets) to better understand their condition when it does not meet criteria for MDS. It may help improve how persistent blood count problems are evaluated over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have low blood counts in at least one type: red cells, neutrophils (a white cell type), or platelets
- Your low blood counts have been persistent for 4 months or longer
- Your case does not meet the minimum diagnostic criteria for MDS (a specific bone marrow disorder)
- No other blood or non-blood disease can explain your low counts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses repeated blood samples to watch how genetic changes in your blood evolve in lower-risk myelodysplastic syndrome (MDS). It may help doctors understand what mutation changes mean over time for people not on strong cancer-fighting treatments.
This study looks at whether healthy lifestyle changes (such as diet and exercise) can help people with low-risk Myelodysplastic Syndrome (MDS), a condition where the bone marrow doesn't produce enough healthy blood cells. It may improve anemia and overall well-being.
This study follows adults with autoimmune blood problems like autoimmune hemolytic anemia, immune thrombocytopenia, and autoimmune/neutropenia to see how diagnosis and care work over time. You may be asked to complete follow-up visits for up to 3 years.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.